Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and use therefor

Abstract

Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.

1 . A continuous hybridoma cell line which secretes monoclonal antibodies which specifically bind to carcinoma specific antigen SK1.  
     
     
         2 . The hybridoma of  claim 1 , wherein the hybridoma is ATCC HB 10905.  
     
     
         3 . A monoclonal antibody which specifically binds to SK1.  
     
     
         4 . The monoclonal antibody of  claim 3 , which is human.  
     
     
         5 . The monoclonal antibody of  claim 4 , having the specificity of a monoclonal antibody produced by hybridoma cell line ATCC HB 10905.  
     
     
         6 . The monoclonal antibody of  claim 4 , wherein the monoclonal antibody is produced by hybridoma cell line ATCC HB 10905.  
     
     
         7 . An anti-idiotypic antibody to the antibody of  claim 3 .  
     
     
         8 . A method of detecting SK1 which comprises contacting a source suspected of containing SK1 with a diagnostically effective amount of detectable labeled antibody or fragment thereof, wherein the antibody specifically binds to SK1 and determining whether the antibody binds to the source.  
     
     
         9 . The method of  claim 8 , wherein the antibody is produced by hybridoma cell line ATCC HB 10905.  
     
     
         10 . The method of  claim 8 , wherein the detecting is in vivo.  
     
     
         11 . The method of  claim 10 , wherein the detectable label is selected from the group consisting of a radioisotope and a paramagnetic label.  
     
     
         12 . The method of  claim 8 , wherein the detecting is in vitro.  
     
     
         13 . The method of  claim 12 , wherein the detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a colloidal metal, a chemiluminescent compound, a bioluminescent compound and an enzyme.  
     
     
         14 . A method of ameliorating malignant disease in an animal which comprises administering to the animal a therapeutically effective amount of a monoclonal antibody or fragment thereof, wherein said antibody specifically binds to SK1.  
     
     
         15 . The method of  claim 14 , wherein the malignant disease is a carcinoma.  
     
     
         16 . The method of  claim 14 , wherein the antibody is human.  
     
     
         17 . The method of  claim 14 , wherein the monoclonal antibody has the specificity of the monoclonal antibody produced by hybridoma cell line ATCC HB 10905.  
     
     
         18 . The method of  claim 14 , wherein the monoclonal antibody is produced by hybridoma cell line ATCC HB 10905.  
     
     
         19 . The method of  claim 14 , wherein the administration is parenteral.  
     
     
         20 . The method of  claim 18 , wherein the parenteral administration is by subcutaneous, intramuscular, intraperitoneal, intracavity, transdermal, or intravenous injection.  
     
     
         21 . The method of  claim 14 , wherein the administration is at a dosage of about 0.01 mg/kg to about 2000 mg/kg/dose.  
     
     
         22 . The method of  claim 14 , wherein the antibody is administered in combination with effector cells.  
     
     
         23 . The method of  claim 14 , wherein the monoclonal antibody is therapeutically labeled.  
     
     
         24 . The method of  claim 23 , wherein the therapeutic label is selected from the group consisting of a radioisotope, a drug, an immunomodulator, a biological response modifier, a lectin, and a toxin.  
     
     
         25 . The method as in any of claims  14 ,  22  and  23 , wherein the antibody is administered substantially contemporaneously in combination with a therapeutic agent.  
     
     
         26 . The method of  claim 25 , wherein the therapeutic agent is selected from the group consisting of a radioisotope, a drug, an immunomodulator, a biological response modifier, a lectin, and a toxin.  
     
     
         27 . Antigen SK1 in substantially pure form and mixtures and salts thereof.  
     
     
         28 . The SK1 of  claim 27  having a molecular weight of 42-46 kD as determined by sodium dodecyl sulfate polyacrylamide gel eletrophoresis under reducing conditions.  
     
     
         29 . The SK1 of  claim 27  comprising an epitope which is specifically bound by a monoclonal antibody having the specificity of a monoclonal antibody produced by hybridoma cell line ATCC HB 10905.  
     
     
         30 . A method of ameliorating malignant disease in an animal which comprises immunizing the animal with an immunogenically effective amount of Sk1.  
     
     
         31 . A method of ameliorating malignant disease in an animal which comprises immunizing the animal with an immunogenically effective amount of the anti-idiotypic antibody of  claim 7 .  
     
     
         32 . A pharmaceutical composition which comprises a therapeutically effective amount of the monoclonal antibodies as in any of claims  3 - 7 , together with a pharmacological carrier.  
     
     
         33 . A pharmaceutical composition comprising an immunogenically effective amount of SK1, together with a pharmacological carrier.